Inhibition of FGFR2, which is widely expressed in human breast cancers, can be combined preclinically with immune checkpoint antibodies to enhance anticancer immunotherapy, warranting clinical evaluation of personalized targeted therapy. Here, FGFR2 is linked to breast cancer.